NCT02710747

The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Guangdong Provincial People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To value the accuracy of the dosing algorithm published by the International Warfarin Pharmacogenetics Consortium in Chinese patients after heart valve replacement. To value the accuracy of warfarin pharmacogenomics algorithm by the algorithm calculated dose and actual dose in the Chinese patients.

Detailed description

The dosing algorithm published by the International Warfarin Pharmacogenetics Consortium hadn't been verifying by a standard randomized prospective study in Chinese patients after heart valve replacement. And, warfarin will affect people's coagulation, so that probably increase the drainage. We'll analyse the interaction of patients' PT-INR or drainge and oral warfarin dosing.

Conditions

• Heart Valve Disease
• Older Than 18-years-old
• Without Any Liver or Kidney Diseases

Interventions

Type	Name	Description
GENETIC	CYP2C9;VKORC1

Timeline

• Start date: 2015-01-01
• Primary completion: 2016-06-01
• Completion: 2016-07-01
• First posted: 2016-03-17
• Last updated: 2016-03-17

Locations

1 site across 1 country: China